PL3484862T3 - Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią - Google Patents

Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią

Info

Publication number
PL3484862T3
PL3484862T3 PL17831578T PL17831578T PL3484862T3 PL 3484862 T3 PL3484862 T3 PL 3484862T3 PL 17831578 T PL17831578 T PL 17831578T PL 17831578 T PL17831578 T PL 17831578T PL 3484862 T3 PL3484862 T3 PL 3484862T3
Authority
PL
Poland
Prior art keywords
hyperuricemia
gout
compositions
treating
compounds
Prior art date
Application number
PL17831578T
Other languages
English (en)
Inventor
Shunqi Yan
Li-Tain Yeh
Robert Orr
Original Assignee
Arthrosi Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthrosi Therapeutics, Inc. filed Critical Arthrosi Therapeutics, Inc.
Publication of PL3484862T3 publication Critical patent/PL3484862T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PL17831578T 2016-07-18 2017-07-12 Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią PL3484862T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363473P 2016-07-18 2016-07-18
PCT/US2017/041763 WO2018017368A1 (en) 2016-07-18 2017-07-12 Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
EP17831578.4A EP3484862B1 (en) 2016-07-18 2017-07-12 Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia

Publications (1)

Publication Number Publication Date
PL3484862T3 true PL3484862T3 (pl) 2022-01-31

Family

ID=60992707

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17831578T PL3484862T3 (pl) 2016-07-18 2017-07-12 Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią

Country Status (16)

Country Link
US (7) US10239854B2 (pl)
EP (2) EP3957629B1 (pl)
JP (3) JP2019524747A (pl)
KR (1) KR102610573B1 (pl)
CN (3) CN113214198B (pl)
AU (1) AU2017298142B2 (pl)
CA (1) CA3030821C (pl)
DK (1) DK3484862T3 (pl)
EA (1) EA201990333A1 (pl)
ES (2) ES2897968T3 (pl)
IL (1) IL264268B (pl)
MX (1) MX391878B (pl)
PL (1) PL3484862T3 (pl)
PT (1) PT3484862T (pl)
SG (1) SG11201900405XA (pl)
WO (1) WO2018017368A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
CN113214198B (zh) 2016-07-18 2022-12-23 广州瑞安博医药科技有限公司 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
CA3121624A1 (en) * 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
US12145917B2 (en) * 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EP3968989A4 (en) * 2019-05-14 2022-12-28 Arthrosi Therapeutics, Inc. COMPOUND FOR TREATMENT OF GOUT OR HYPERURICEMIA
WO2020253659A1 (en) * 2019-06-17 2020-12-24 Fochon Pharmaceuticals, Ltd. Heterocyclic derivatives and use thereof
CN116648445A (zh) * 2020-06-10 2023-08-25 安索治疗公司 治疗或预防慢性肾脏病的方法
WO2021252630A1 (en) * 2020-06-10 2021-12-16 Arthrosi Therapeutics, Inc. Methods for treating or preventing chronic kidney disease
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
US20250066316A1 (en) * 2021-12-02 2025-02-27 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN118974028A (zh) * 2021-12-30 2024-11-15 广州瑞安博医药科技有限公司 用于治疗痛风或高尿酸血症的化合物的制备
WO2023149549A1 (ja) * 2022-02-03 2023-08-10 国立大学法人富山大学 新規医薬組成物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023985A (en) 1911-05-29 1912-04-23 Louis Emile Beaulieu Fish-plate bolt.
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
DE19624292A1 (de) * 1996-06-18 1998-01-02 Merckle Gmbh Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1767531A4 (en) * 2004-06-10 2011-01-05 Torii Pharmaceutical Co Ltd 6-HYDROXYBENZBROMARONE OR SALTING MEDICAL COMPOSITIONS CONTAINING THEREOF
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
BRPI0809843A2 (pt) * 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
JP5325065B2 (ja) * 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
GB2484298A (en) 2010-10-05 2012-04-11 Plexus Ocean Syst Ltd Subsea wellhead with adjustable hanger forming an annular seal
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US20150031768A1 (en) 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2014113407A2 (en) * 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
CN105579037A (zh) * 2013-05-31 2016-05-11 武田制药美国有限公司 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
WO2015134467A1 (en) * 2014-03-05 2015-09-11 The Trustees Of Princeton University Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
MX2017001103A (es) 2014-07-31 2017-04-27 Merck Patent Gmbh Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
CN104262305B (zh) 2014-09-16 2016-06-08 东北制药集团股份有限公司 一种苯溴马隆晶型a及其制备方法
CN104311516B (zh) 2014-09-16 2017-01-11 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
CN113214198B (zh) * 2016-07-18 2022-12-23 广州瑞安博医药科技有限公司 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
US12145917B2 (en) 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia

Also Published As

Publication number Publication date
ES2897968T3 (es) 2022-03-03
KR102610573B1 (ko) 2023-12-05
KR20190020170A (ko) 2019-02-27
IL264268A (en) 2019-02-28
US20190169150A1 (en) 2019-06-06
AU2017298142A1 (en) 2019-02-28
US20220396558A1 (en) 2022-12-15
CA3030821A1 (en) 2018-01-25
ES2964344T3 (es) 2024-04-05
SG11201900405XA (en) 2019-02-27
US10239854B2 (en) 2019-03-26
WO2018017368A1 (en) 2018-01-25
US20190040030A1 (en) 2019-02-07
DK3484862T3 (da) 2021-11-08
JP2019524747A (ja) 2019-09-05
EP3957629A1 (en) 2022-02-23
EP3484862A4 (en) 2020-01-22
CN116332886A (zh) 2023-06-27
EP3957629B1 (en) 2023-09-06
US20200148659A1 (en) 2020-05-14
EP3484862A1 (en) 2019-05-22
US20240116888A1 (en) 2024-04-11
EP3957629C0 (en) 2023-09-06
CN109790135A (zh) 2019-05-21
JP2020143044A (ja) 2020-09-10
JP7418227B2 (ja) 2024-01-19
EA201990333A1 (ru) 2019-10-31
US20220112171A1 (en) 2022-04-14
CN109790135B (zh) 2023-07-28
MX391878B (es) 2025-03-21
IL264268B (en) 2022-08-01
EP3484862B1 (en) 2021-09-01
CN113214198B (zh) 2022-12-23
JP2022188052A (ja) 2022-12-20
WO2018017368A9 (en) 2019-03-07
CA3030821C (en) 2025-07-08
AU2017298142B2 (en) 2021-11-11
US20230227419A1 (en) 2023-07-20
CN113214198A (zh) 2021-08-06
PT3484862T (pt) 2021-11-17
US10508093B2 (en) 2019-12-17
US11236058B2 (en) 2022-02-01

Similar Documents

Publication Publication Date Title
PL3484862T3 (pl) Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią
ZA201908154B (en) Compounds and compositions for treating conditions associated with nlrp activity
PT3348557T (pt) Imidazo[1,2a]piridinas para o tratamento ou prevenção de hiperuricemia ou gota
LT3283551T (lt) Aktyvintas lignino mišinys, jo gamybos ir naudojimo būdas
SG10201913559VA (en) Methods for treating and preventing c. difficile infection
IL283665A (en) Methods for treating or preventing rheumatism or hyperuricemia
IL287983A (en) 15-hepe or a preparation containing 15-hepe for the treatment or prevention of fibrosis
IL256109A (en) Methods for the treatment or prevention of protopathy
ZA201907975B (en) Agent for preventing or treating tauopathy
PL3129378T3 (pl) Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu
PT3129467T (pt) Ilhéus de porco transgénicos e seus usos para tratar a diabetes
PL3092209T3 (pl) Nawóz mający zredukowaną zawartość biuretu
GB201410099D0 (en) Dock gate
IL262664A (en) Compounds for the prevention of symptoms of vascular diameter change symptoms
IL251648A0 (en) A preparation for treating an anti-material template and a method for creating a template using it
PL3172353T3 (pl) Sposób obróbki elementu azotowanego/azotonawęglanego
HK40008772A (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
PT3414155T (pt) Mordente de corrente melhorado
IL275258A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF VASOMOTOR SYMPTOMS
ZA201802090B (en) A composition and method for treating substrates
ZA201706716B (en) A composition and method for treating substrates
PL3449155T3 (pl) Łącznik łańcucha
GB201405438D0 (en) Herbicidal composition, a method for its preperation and the use thereof
SG10201403858RA (en) Compound, composition and method for treating and/or ameliorating kidney disease